Using Virtual Reality in E-Cigarette and Secondhand Aerosol Prevention Messages: Implications for Emotional Campaign Design.

Vaping has dramatically increased in recent years among young adults. To increase risk perceptions and promote preventive behaviors against vaping and secondhand e-cigarette aerosol (SHA), this study designed and tested virtual reality (VR) messages based on the theory of psychological distance. We randomly assigned 137 participants to see one of three messages: a VR message presenting SHAs impact on the self (VR-Self), a VR message showing SHAs impact on others (VR-Other), and a print advertisement. Risk perceptions and preventive intentions/behaviors were assessed at three different times: before, immediately after, and 1 week after the experimental treatment. All three messages increased desired intentions and risk perceptions immediately, reduced vaping interest both immediately and 1 week after message exposure, and increased behavior to persuade others to quit vaping after a week. Compared with the print advertisement, VR-Other generated less vaping interest immediately following message exposure (ß = 1.40, p = 0.05). After 1 week, VR-Self (ß = 1.62, p = 0.05) and VR-Other (ß = 2.37, p = 0.01) generated less vaping interest than the print advertisement. VR-Other also generated a higher level of perceived harm of SHA (ß = 1.27, p = 0.01) than the print advertisement. VRs advantage over print in reducing vaping interest was increased after 1 week. Although VR-Other generated less emotions, such as fear, than VR-Self (z = 2.48, p = 0.02) and print (z = -2.82, p = 0.02), its persuasiveness was not hindered. Disgust increased the intentions to persuade others to quit vaping immediately after the experimental treatment (ß = 0.85, p = 0.02), and anger aroused by recalling the messages decreased vaping interest 1 week later (ß = -2.07, p = 0.02).

College students and HIV testing: cognitive, emotional self-efficacy, motivational and communication factors.

Most college students have never been tested for HIV, even though they regularly have unprotected sex and multiple sex partners. Theory-based research addressing factors influencing HIV testing among college students is limited. This study explored this topic via a conceptual framework that integrates the health belief model with emotion and communication factors. Data was collected with a sample of four focus group panels, including two male and two female groups (N = 52). Transcripts for the seven discussion questions were produced based on the audio recordings of group sessions. Two research assistants reviewed, summarized and cross-validated the discussion content to address each of the four research questions under study. Students believe HIV to be a severe health threat, but feel 'invincible' about contracting the virus. Their low emotional self-efficacy is a barrier for adopting HIV testing. Gaining social approval and emotional support for making a testing decision can help them overcome the perceived fear, stigma and lack of response efficacy associated with taking the test. Students are open to receiving cues to action via confidential HIV-testing related communication from health professionals or important others as well as media messaging from various sources. Bridging the perceptual-emotional gap between perceived invulnerability and fear can help increase emotional self-efficacy in coping with HIV testing. Normalizing HIV testing as a primary care routine for harm avoidance/reduction will increase perceived benefits of testing. Communicating cues to action will help reinforce HIV testing as a societally approved and socially supported protective behavioral norm.

Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study.

PURPOSE: Response to anticancer therapy is believed to be directly related to the concentration of the anticancer drug in the tumor itself. Assessment of intra-tumor drug pharmacokinetics can be helpful to gain more insight into mechanisms involved in the (in)sensitivity of tumors to anticancer therapy. We explored the pharmacokinetics of 5-fluorouracil in both plasma and tumor tissue during a 5-day continuous infusion of 5-fluorouracil in patients with cancer. Sampling for measurement of 5-fluorouracil in tumor tissue was performed using microdialysis. EXPERIMENTAL DESIGN: In seven patients with an accessible (sub)cutaneous tumor treated with a continuous 5-fluorouracil infusion, plasma and microdialysate samples from tumor and normal adipose tissue were collected over a period of 5 days. RESULTS: For six patients, drug concentrations in both tumor tissue and plasma were available. Concentration-time curves of unbound 5-fluorouracil were lower in tumor tissue compared to the curves in plasma, but exposure ratios of tumor tissue versus plasma increased during the 5-day infusion period. The presence of circadian rhythmicity of 5-fluorouracil pharmacokinetics in the tumor itself was demonstrated as 5-fluorouracil concentrations in tumor extracellular fluid were higher during the night than during daytime. CONCLUSION: Microdialysis was successfully employed in patients with cancer during a continuous 5-day 5-fluorouracil infusion. Plasma and tumor pharmacokinetics of 5-fluorouracil differed substantially with increasing 5-fluorouracil concentrations in tumor over time, possibly resulting from a lowered interstitial fluid pressure by 5-fluorouracil itself. This microdialysis 5-fluorouracil model might be useful to monitor the effect of drug delivery modulating strategies in future studies.